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Abstract: Bacterial infections due to bone replacement surgeries require modifications of bone
cement with antibacterial components. This study aimed to investigate whether the incorporation
of gentamicin or nanometals into bone cement may reduce and to what extent bacterial growth
without the loss of overall cytocompatibility and adverse effects in vitro. The bone cement Cemex
was used as the base material, modified either with gentamicin sulfate or nanometals: Silver or
copper. The inhibition of bacterial adhesion and growth was examined against five different bacterial
strains along with integrity of erythrocytes, viability of blood platelets, and dental pulp stem cells.
Bone cement modified with nanoAg or nanoCu revealed greater bactericidal effects and prevented
the biofilm formation better compared to antibiotic-loaded bone cement. The cement containing
nanoAg displayed good cytocompatibility without noticeable hemolysis of erythrocytes or blood
platelet disfunction and good viability of dental pulp stem cells (DPSC). On the contrary, the nanoCu
cement enhanced hemolysis of erythrocytes, reduced the platelets aggregation, and decreased DPSC
viability. Based on these studies, we suggest the modification of bone cement with nanoAg may be a
good strategy to provide improved implant fixative for bone regeneration purposes.
Keywords: bone cement; nanometals; antibacterial properties; cell viability; hemolysis
1. Introduction
Human ageing associated with gradual weakening of the bones and an increasing number of
accidents contributes to the fact that bone cement (BC) has been gaining broader applications in medicine.
Acrylic BC based on polymethyl methacrylate (PMMA) is a particularly common biomaterial due to its
easy processability, favorable mechanical properties, and biostability in the human body. However,
it is a non-biodegradable material with relatively poor adhesion to surfaces, and its polymerization
can damage the surrounding tissue [1–3]. Currently, bone cement is used for the fixation of implants,
antibiotic delivery system, cavity or bone defect fillers, coating on metal implants, and vertebral
stabilization [4–6]. It is generally accepted that clinically successful BC should be a biocompatible
material, but some bone cement components may be toxic to human body, such as unreacted methyl
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methacrylate (MMA) monomer or certain additives, i.e., N,N-dimethyl-p-toluidine, benzoyl peroxide,
barium sulfate, as well as free radicals released during the polymerization process. The most recognized
negative responses include tissue necrosis, fibrosis, or impaired bone remodeling in the vicinity of the
implant [7–9]. When introduced into the body, BC may affect blood components, and some BCs used
for implantation may affect hemostasis due to the hyperactivation or even inactivation of platelets [10].
The process of platelet activation is essential for maintaining hemostasis and proper wound healing.
Activated platelets also release several growth factors, such as TGF-β1, PDGF, IGF-I, IGF-II, which
are involved in bone remodeling, including osteogenesis, osteoblasts differentiation, and inhibition
of osteoclastic bone resorption [10,11]. However, pathological platelet overactivation contributes to
the development of micro- and macro-angiopathies leading to vascular complications whereas any
BC-related platelet inactivation is associated with the risk of bleeding [12,13].
The treatment of complicated fractures with BC is always associated with the opening of the
body’s layers. Hence, there is a risk of hospital-acquired infection. Furthermore, the biomaterials
(especially BC) handling may lead to the adhesion of bacteria to their surface. It is assumed that
the frequency of orthopedic infection is close to 2%, however, for bone substitutes, it has already
reached about 13% [14]. Most of these bacterial infections are due to a group of multi-drug resistant
clinical bacterial strains, which also produce biofilm. The implant-related osteomyelitis is mainly
caused by methicillin-resistant Staphylococcus aureus that is exceptionally complicated to cure and
usually requires surgical debridement as well as a high dose of locally delivered antibiotics [15,16].
Antibiotic-loaded BC (BC-A) (with commercial or manually added antibiotic) is currently the gold
standard that significantly reduces the adhesion and proliferation of bacterial colonies. However, the
vast majority of antibiotic particles are released from the BC-A in the first few postoperative hours and
thus the dose is too small and ineffective in the next hours or days after implantation. The bacteria
may also produce biofilm structures that can significantly reduce the antibiotic’s effects. There is
an emerging problem of increased bacterial resistance as well [16–18]. Therefore, newer and more
effective solutions in implantology are currently sought, including antimicrobial peptides, therapeutic
antibodies, phage therapy, quorum sensing inhibitor, as well as antimicrobial nanoparticles [19,20].
Particularly noteworthy are nanometals, such as nanoAu, nanoAg, nanoCu, nanoTi, or nanoZn, which
are characterized by high antibacterial abilities and a broad spectrum of activity [19–22]. BC containing
nanometals (BC-N) seem to be a better solution than BC-A, due to better bactericidal properties.
The latter are attributed to the release of free metals ions, direct cell membrane damage, uptake
of nanoparticles into cells or generating reactive oxygen species (ROS). The above processes may
lead to bacteria cell lysis and its mortality, but they may also affect cells of human body [23–25].
In general, bacteria are not resistant to nanometals [26–28] and nanoAG and nanoCu are now
extensively investigated for their antibacterial activity [29–31]. These metals are experimentally
incorporated into various materials, such as polyurethanes or polypropylene composites, dental
adhesives, bioglass, and hydroxyapatite coatings [32–36]. Bone cements can also be enriched with the
addition of metal nanoparticles, but so far the investigation of BC containing nanometals or their oxides
are scarce. Several studies have been conducted with nanoTiO2, nanoMgO, nanoZnO, nanoAl2O3,
nanoAg, and nanoAu to improve mechanical properties of implants or to obtain bactericidal activity
but results are often inconclusive [37–44]. The selection of optimal BC modification is thus crucial to
provide its safety, protection against infections and effective wound healing in patients [26,45].
In this research, we approach the problem of antibacterial protection along with a good
biocompatibility of bone cements by comparing the biological properties of PMMA modified with
either gentamycin sulfate or nanoAg and/or nanoCu. So far, very few reports investigated nanoCu
modifications of BC and we have not come across the investigations regarding combined nanoAg and
nanoCu BC modifications. Antibacterial activity along with erythrocytes integrity, viability of platelets,
and dental pulp cells are investigated for the preliminary assessment of modified BC suitability for
bone regenerative purposes.
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2. Materials and Methods
2.1. Cement Preparation
The PMMA bone cement Cemex (Tecres Company, Verona, Italy) was used as the base material.
It was then either modified by us with gentamicin sulfate (Sigma Aldrich, Steinheim, Germany;
designated BC-A) or nanometals: Silver or copper (MkNano, Mississauga, ON, Canada; designated
BC-N). The latter were designated BC-NpAg, BC-NpCu, BC-NpAg+NpCu. The average particle size
of both nanometals was 50 nm, and their purity was 99.9%. The basic properties of nanometals were
obtained from the technical sheet. Bone cement specimens were prepared following the manufacturer’s
instructions and according to the international standard ISO 5833:2002 [46]. For the modified BCs, the
protocol included the addition of modifiers (nanometals or antibiotic) to the cement powder (1.5%
or 3% weight/weight) and then manually mixing for about 1 min or up to the visual observation of
even distribution of powders. The applied contents of modifiers and bone cement components are
presented in Table 1. The used contents of gentamycin and nanometals were set up based on some
previous studies [47,48].








Bone Cement Modified with Nanometals
nanoAg/BC-NpAg/ nanoCu/BC-NpCu/ nanoAg &nanoCu/BC-NpAg+Cu/
Powder Component (% w/w)
Polymethyl
methacrylate 84.30 83.05 81.77 83.05 81.77 83.05 81.77 83.05
Barium sulfate 13.00 12.80 12.61 12.80 12.61 12.80 12.61 12.80
Benzoyl peroxide 2.70 2.65 2.62 2.65 2.62 2.65 2.62 2.65
Gentamicin sulphate ——- 1.50 3.00 ——- ——- ——- ——- ——-
NanoAg ——- ——- —— 1.50 3.00 ——- ——- 1.15
1.50NanoCu ——- ——- —— ——- —— 1.50 3.00 0.35




2.2. Antibacterial Properties Testing on Orthopaedic Bacteria
2.2.1. Bacterial Growth Inhibition
Inhibition of bacterial growth was checked by measuring the turbidity of cultured bacterial broth
according to McFarland standards [49]. The study consisted of incubating the tested BCs in a bacterial
solution and measuring its optical density. The Staphylococcus aureus strain (ATCC 29213) was used
for these tests and the initial concentration of bacteria was 1.5 × 108 CFU/mL, which corresponds to
0.5 McFarland index (iMS). The McFarland index is the assumed turbidity of the solution referring
to the number of bacteria. Before testing, the BCs were sterilized in an autoclave Sucerex HP 446-1V
(Münster Medizin Mechanik, Münster, Germany) at 120 ◦C for 30 min. The experiment was performed
using three specimens for each type of BC (n = 3) in disk form (10 mm diameter, 2 mm thick) and 2 mL
of bacterial solution. The size of the specimens was reduced vs. those shown in Figure 1 to adjust
samples to the Eppendorf tube size. The assessment of bacterial effectiveness of modifications was
carried out on samples incubated with BC specimens with a concentration of 1.5% w/w of modifiers.
The bacteria were suspended in Trypticase Soy Broth (Merck, Darmstadt, Germany) and incubated at
37 ◦C. The DensiChEK Plus (BioMerieux, Montreal, QC, Canada) was used for measurements of optical
density of bacteria suspension and readings were made after 0.5, 2, 4, 6, and 24 h. The maximum
measuring range of this device is 4 iMS. As control, incubated bacteria suspension without material
were used. Following the CLSI Standard M7 [49], the number of bacteria in present tests are calculated
based assuming that if iMs equalling 1, the number of bacteria is 3 × 108 CFU/mL, and there is a direct
relation between iMS and the number of bacteria. In pursuance of the recommendations for optical
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densitometry methods, some measurements were rejected as positively false if the material affected the
color of the solution.
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2.2.2. Inhibition of Bacterial Adhesion to the Surface
Evaluation of bacterial adhesion inhibition was performed by immersing the specimens in a
bacterial solution that consisted of five clinically isolated bacterial strains: Staphylococcus aureus,
Staphylococcus epidermidis, Enterococcus faecalis, Enterobacter cloacae, and Pseudomonas aeruginosa
(supplied by the Specialized Hospital in Kos´cierzyna, Poland). A total of 10 mL of each bacterial
strains suspensions were taken (inoculum—1 × 108 CFU mL−1) and added to 50 mL of the liquid
medium—Tryptic Soy Bulion (Merck, Darmstadt, Germany). The experiment was performed using
one specimen for BC, BC-A, and BC-NpAg at a concentration of 1.5% w/w. Before the tests, specimens
were sterilized in an autoclave at 120 ◦C for 30 min. The BCs in the form of disks (20 mm diameter,
2 mm thick) were placed in a 2-mL bacterial solution. Then the samples were incubated at 37 ◦C for
14 days. The adhesion of bacteria to the surface was observed using a scanning electron microscope
JSM-7800F (Jeol, Tokyo, Japan).
2.3. Cytocompatibility Testing on Blood Components
2.3.1. Blood Collection and Preparation
Red blood cells (RBCs) and platelets (PLTs) were obtained from erythrocyte contaminated buffy
coats obtained from the Regional Blood Centre in Gdan´sk and provided as by-products of whole blood
fractionations according to Regional Blood Blank institutional permission (M-073/17/JJ/11). Whole blood
was collected from healthy volunteers in accordance with the Declaration of Helsinki under an approved
Regional Bank review board protocol in standard acid citrate dextrose solutions. RBCs and PLTs were
fractionated according to standards of Blood Banks [50]. The number of erythrocytes and platelets was
estimated with a hemocytometer Superior CE (Marienfeld, Lauda-Königshofen, Germany).
2.3.2. In Vitro Hemolysis Assay and Evaluation of Erythrocyte Morphology
Erythrocytes (3 × 109 cells/mL) were placed in 2 mL tubes containing the autoclaved BC specimens
in disk form (10 mm diameter, 2 mm thick) and incubated at 37 ◦C for up to 24 h. The size of the
specimens was reduced vs. those shown in Figure 1 to adjust samples to the Eppendorf tube size. RBCs
treated with 2% Triton were used as a positive control (i.e., 100% hemolysis). Briefly, aliquots RBCs
exposed to BC specimens for 2 h and 24 h were transferred to microscope slides and the erythrocyte
morphology was assessed by light microscopy. Erythrocytes morphology assessment tests were carried
out on samples incubated with BC specimens with a concentration of 1.5% w/w. The remaining blood
samples were centrifuged at 100× g at room temperature for 3 min to let the erythrocytes sediment
and supernatants were taken for assessment of hemolysis at a wavelength of 540 nm by Ultrospect
3000pro spectrophotometer (Amersham-Pharmacia-Biotech, Cambridge, UK). The red color of the
supernatant indicates damage to RBCs membrane and the intensity of the red color, measured at
540 nm, is assumed as the intensity of hemolysis. According to literature absorbance values which did
not exceed the value of 1 were assumed negative for hemolysis [51].
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2.3.3. Platelet Aggregation
Platelets (3 × 108/mL) were placed in 2 mL tubes containing the autoclaved BC specimens in disk
form (10 mm diameter, 2 mm thick) and preincubated at 37 ◦C for 2 min and 2 h. This experiment was
carried out on BC specimens containing 1.5% of the modifiers additive. After this exposure platelets
were transferred to cuvettes for aggregation and resting or thrombin-induced aggregation of platelets
(i.e., 0.05 IU) was conducted for 10 min on an aggregometer APACT (Labor, Hamburg, Germany).
2.3.4. MTT Platelet Viability Test
The analyses of platelet viability were performed by application of thiazolyl blue tetra-zolium
bromide (MTT assay; Sigma Aldrich, Steinheim, Germany). Briefly, PLT samples after expose to
BC specimens were suspended in phosphate buffered saline (PBS) buffer (Sigma Aldrich, Steinheim,
Germany) and plated at a density of 2 × 107 cells. After 4 h of incubation at 37 ◦C in the dark, a dimethyl
sulfide/sodium dodecyl sulfate (Sigma Aldrich, Steinheim, Germany) DMS/SDS solution (20%/3%,
pH 4.8) was added to dissolve the reduced formazan product, which reflects cells mitochondrial
activity and viability. Finally, the absorbance at 570 (which reflects the blue-violet color for reduced
formazan) and 690 nm (which reflects the background from chemicals used in the method) was read in
a microplate VICTOR 1420 Multilabel Counter (PerkinElmer, Kraków, Poland) [52]. The color intensity
of the solution is proportional to the number of viable cells. The results were compared to control
(BC—unmodified bone cement) and assumed as 100% of platelet viability.
2.4. Cytocompatibility Testing in Cultures of Dental Pulp Stem Cells (DPSC)
2.4.1. DPSC Collection and Preparation
Bone cements are widely used in both orthopedic and dental surgeries [2,15,53]. We chose human
dental pulp stem cells (DPSC), which are routinely obtained in one of our laboratories and they are
a good model of adult stem cells with great potential to regenerate bone [54]. DPSC were obtained
from the molar tooth of an adult 31-year-old female donor in agreement with the Polish Research
Ethics Board; approval no. 1072.6120.253.2017). The cells were isolated according to a Bakkar protocol
(2017) [55], expanded in culture using alpha-MEM supplemented with 15% fetal bovine serum (FBS),
0.1 mM l-ascorbic acid phosphate and 1% antibiotics (Penicilin-Streptomycin—10,000 U/mL, Thermo
Fisher Scientific, Waltham, MA, USA). When the cells reached a confluent monolayer, they were
lifted from culture flasks using 0.25% Trypsin-EDTA, counted and seeded directly on the surface of
the materials. The cells were then used for preliminary assessment of their proliferation potential,
adhesion, and morphology on BC surfaces. Briefly, the cell culture experiments were performed using
three specimens for each type of BC (n = 3) in disk form (20 mm diameter, 2 mm thick). Before testing,
the specimens were sterilized by autoclaving at 120 ◦C for 30 min. The specimens were then placed in
separate wells of 24-well culture plates and covered by 2 × 104 DPSC suspended in 1 mL of culture
medium (i.e., alpha-MEM supplemented with 10% fetal bovine serum (FBS) and antibiotics). The cells
were incubated at 37 ◦C in an atmosphere containing 5% CO2 for up to 5 days. The medium was
aspirated and replaced with a fresh one every 48 h.
2.4.2. MTS Cell Viability Test
DPSC were tested for viability after 4 days of culture. Cell viability was evaluated using CellTiter
96 Aqueous One Solution Cell Proliferation Assay (MTS, Promega, Kraków, Poland). Each material
sample in the culture plate was covered with 400 µL of MTS solution diluted ten times in phenol-red
free alpha-MEM. The plate was then incubated at 37 ◦C in a culture incubator until the development
of a brownish color of the MTS solution. The intensity of the developed color is proportional to the
number of actively metabolizing live cells. After 30 min, the MTS solution from individual wells was
transferred to clear 96-well plates, and its absorbance was measured at 490 nm, where is the maximum
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absorbance of the solution. The results were expressed as a % change in the live cell number compared
to the results obtained for cells grown on BC (assumed as 100%).
2.4.3. Evaluation of DPSC Cells Morphology
To evaluate the potential morphological changes of cells on contact with the materials, we used
larger culture wells (12-well plates) and a higher DPSC cell suspension was applied for this study (i.e.,
4 × 104 cells suspended in 2 mL of medium). The morphology of DPSC cells in close proximity to the
materials was observed with contrast-phase inverse microscope Axiovert 40 CFL (Zeiss, Oberkochen,
Germany) at culture days 1, 3, and 5. For control, the cells were also seeded into standard culture
plates without any specimens. Photographs were taken for DPSC samples cultured on BC specimens
with a concentration of 3% w/w of modifiers.
2.4.4. Adhesion Assessment of DPSC Cells to the Surface
Cell adhesion to the BC surface was evaluated after 24 h incubation of BC specimens with
DPSC cells using fluorescence microscope, contrast-phase inverse microscope Axiovert 40 CFL (Zeiss,
Oberkochen, Germany), and scanning electron microscope JSM-7800F (Jeol, Tokyo, Japan). For these
analyses cells were seeded directly on materials in the form of disks (20 mm diameter, 2 mm thick)
in separate wells of 24-well culture plates a the density of 2 × 104 DPSC in 1 mL of culture medium.
After 24 h incubation cells were either directly observed under contrast-phase microscope or fixed
and/or stained for SEM or fluorescence microscope observations, respectively. These experiments
were carried out on samples cultured with BC and BC-NpAg at 3% w/w. For fluorescent microscopy,
cell cultures on material specimens were fixed with a 4% solution of formaldehyde (Sigma Aldrich,
Steinheim, Germany) and incubated for 30 min at 37 ◦C. After washing three times with PBS solution,
0.03% Evans blue stain solution (Sigma Aldrich, Steinheim, Germany) was added for 20 min followed
by rinsing three times with PBS solution to remove excess strain [56]. For SEM analyses cultures were
fixed with a solution composed of 2% formaldehyde, 2% glutaraldehyde, and 2% cacodyl buffer (Sigma
Aldrich, Steinheim, Germany) for 24 h at 4 ◦C. Next the fixed cultures were rinsed three times with PBS
and dehydrated in increasing concentrations of ethyl alcohol (Sigma Aldrich, Steinheim, Germany) for
30 min [57].
2.5. Statistical Method
Statistical analysis of the data was performed using commercial software (SigmaPlot 14.0, Systat
Software, San Jose, CA, USA). The Shapiro–Wilk test was used to assess the normal distribution of
the data. All of the results were presented as a mean ± standard deviation (SD) and were statistically
analyzed using one-way analysis of variance (one-way ANOVA). Multiple comparisons versus the
control group between means were performed using the Bonferroni t-test with the statistical significance
set at p < 0.05.
3. Results
3.1. Antibacterial Properties Testing on Orthopedic Bacteria
3.1.1. Bacterial Growth Inhibition
The assessment of the inhibition of bacterial growth in solution at its initial stage was carried
out. In the case of bacteria incubated in the control sample and with BC, their rapid multiplication
to 4 iMS (which corresponds to 12 × 108 CFU/mL) was observed within 4 h. In the case of modified
BC, the growth of bacteria was slowed down. After 24 h, the turbidity value of the solution was
1.33 iMS for BC-NpAg (about 3.9 × 108 CFU/mL; turbidity about 93.1 NTU), 1.52 iMS for BC-A
(about 4.6 × 108 CFU/mL; turbidity about 119.4 NTU), and 0.91 iMS for BC-NpAg+Cu (about 2.7 × 108
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CFU/mL; turbidity about 60.2 NTU). Hence, a significant inhibition of bacterial growth in the initial
incubation phase with the material is confirmed (Table 2).
Table 2. McFarland standard values specifying the number of Staphylococcus aureus bacteria during
incubation with tested specimens: Modified bone cements—1.5% w/w of modifiers additive (n = 3;
mean ± SD; * significantly different from control—p < 0.05).
McFarland Index
Time (h) K BC BC-NpAg BC-NpCu BC-NpAg+Cu BC-A
0 0.5 ± 0.01
0.5 0.68 ± 0.01 0.71 ± 0.02 0.68 ± 0.01 0.70 ± 0.02 0.60 ± 0.01 0.65 ± 0.01
2 1.93 ± 0.03 1.64 ± 0.01 1.10 ± 0.01 1.95 ± 0.01 0.77 ± 0.02 1.24 ± 0.01
4 >4 3.48 ± 0.02 1.22 ± 0.02 × 0.79 ± 0.02 1.35 ± 0.02
6 >4 >4 1.29 ± 0.01 × 0.80 ± 0.03 1.48 ± 0.02
24 >4 >4 1.33 ± 0.02 * × 0.91 ± 0.03 * 1.52 ± 0.02 *
* Statistical analysis was performed between groups and control after 24 h and the group, where the statistically
significant difference occurred was marked. ×—measurement rejected due to the color of the solution.
3.1.2. Inhibition of Adhesion of Bacteria to the Surface
The long-term antibacterial effect was checked by bacterial adhesion to the surface of BCs after 14
days. In the case of BC-A, a decrease in the bacteria staked to the surface was observed. However, even
better effects were observed for BC-NpAg (Figure 2). Additionally, on the surface of BC, formation of
the biofilm structure appeared (Figure 2).
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Figure 2. Comparison of bacterial adhesion to the surface of the tested materials after 14 days of
incubation in bacterial suspension: Modified bone cements—1.5% w/w of modifiers additive (SEM
200×).
3.2. Cytocompatibility of Bioactive Bone Cements with Erythrocytes and Blood Platelets
3.2.1. Effect of Bone Cement Modifications on In Vitro Hemolysis and Erythrocyte Morphology
As presented in Figure 3, after 2 h exposure of RBCs to BC, 1.5% and 3% BC-NpAg, 1.5% and 3%
BC-NpCu, and 1.5% and 3% BC-A hemolysis of erythrocytes was not observed expect for erythrocytes
incubated with BC-NpAg+Cu (p < 0.05). After 24 h of RBCs incubation with the specimens, there
was significant hemolysis in RBCs exposed to 1.5% and 3% BC-NpCu as well as BC-Ag+Cu (p < 0.05).
The morphology of erythrocytes was assessed after a longer incubation with specimens (24 h) (Figure 4).
There was no anisocytosis of RBCs exposed to the BC specimens. However, there was evidence of
RBCs poikilocytosis after incubation with: BC-NpAg 1.5% and 3%, BC-NpCu 1.5% and 3%, BC-A 1.5%
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and 3%, as well as BC-NpAg+Cu. After 24 h incubation with the specimens containing 1.5% and 3%
nanoAg, 1.5% and 3% nanoCu, and 1.5% and 3% gentamicin evoked RBCs membrane shape changed
similar to echinocytes or acanthocytes. Interestingly, the combination of both nanometals Ag and Cu
(1.5%) modified RBCs shape differently and similar to codocytes or target cells.
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(A) Hemolysis at 2 h and 24 h incubation of materials with erythrocytes—the line indicates the threshold
value above which the hemolysis take place (n = 5; data are the means ± SD; * significantly different
from negative control—p < 0.05); (B) Hemolysis after 24 h incubation of specimens with erythrocytes
(the presented pictures are representative for 5 experiments).
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3.2.2. Effect of Bone Cement Modifications on In Vitro Platelet Aggregation and Their Viability
There was no spontaneous platelets aggregation after 2 min and 2 h exposure to BC, BC-NpAg 1.5%,
BC-NpCu 1.5%, and BC-A 1.5% (Table 3). Short (2 min) exposure of PLTs to BC, BC-NpAg, BC-NpCu,
and BC-A did not significantly change both the early phase and the late phase of thrombin-evoked
aggregation (Table 3). However, longer (2 h) PLTs incubation with BC-NpCu 1.5% reduced the early
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phase of aggregation by 87% and the late phase of aggregation by 67% (p < 0.05) (Table 3). Similarly,
BC-A 1.5% reduced thrombin-induced platelets aggregation by 67% and 41% in the early phase and the
late phase (p < 0.05) (Table 3). Moreover, an MTT test was performed after 2 h incubation specimens
with platelets. A significant reduction was found only in the case of BC-NpCu (about 60% compared
to the control; p < 0.05; data unpublished).
Table 3. Effect of cement specimens on platelet aggregation: Modified bone cements with 1.5% w/w of
modifiers/(n = 5; data are the means ± SD; * significantly different from negative control—p < 0.05).
K BC BC-NpAg BC-NpCu BC-A
2′ 2 h 2′ 2 h 2′ 2 h 2′ 2 h 2′ 2 h
Spontaneous aggregation (%) 1 ± 1 2 ± 1 1 ± 1 2 ± 1 2 ± 1 2 ± 1 2 ± 1 2 ± 1 1 ± 1 2 ± 1
Trombin-evoked early phase
of aggregation (1 min) (%) 43 ± 6 31 ± 8 39 ± 3 23 ± 11 33 ± 8 23 ± 6 28 ± 13 4 ± 2 * 32 ± 14 10 ± 3 *
Thrombin-evoked late phase
of aggregation (10 min) (%) 76 ± 9 67 ± 7 74 ± 8 64 ± 10 70 ± 8 49 ± 9 69 ± 6 22 ± 17 * 67 ± 13 39 ± 7 *
3.3. Cytocompatibility of Bioactive Bone Cement with Dental Pulp Stem Cells
3.3.1. MTS Cell Viability Test
The viability of dental pulp stem cells (DPSCs) after 3 days culture on material specimens, is
presented in Figure 5.Nanomaterials 2019, 9, x FOR PEER REVIEW 10 of 18 
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BC 1.5% and 3% NpAg showed similar to BC cell viability and there was no statistical difference
cells grown (Figure 5). However, the other modifications (BC-A, BC-NpCu, as well as BC-NpAg+Cu)
significantly decreased cell viability compared to cells grown on BC (Figure 5).
3.3.2. Evaluation of DPSC Cells Morphology
The morphology of cells grown in close proximity to the materials compared to normal cell
morphology grown on tissue culture plastic (TCP) was evaluated. Photographs taken under a
contrast-phase inverse microscope are shown in Figure 6. Unmodified BC and BC-NpAg did not
affect the DPSC morphology and confluent monolayer could be observed in the proximity of materials
(Figure 6). In contrast, toxicity of nanoCu was found as we observed reduced number of cells and they
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displayed abnormal, rounded morphology (Figure 6). It may be either due to the inability of cells to
adhere or cell detachment due to material dissolution products.
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Figure 6. Evaluation of morphology of cells grown in close proximity to the materials: Modified bone
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3.3.3. Adhesion Assessment of DPSC Cells to the Material Surfaces
Twenty-four hours post cell seeding cells adhered well to BC and BC-NPAg as shown by Figure 7A
staining with Evans Blue and observation with fluorescence microscopy as well as by Figure 7B fixing
and observation with scanning electron microscopy. For all other material modifications, only single
cells were found on the surface.
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Figure 7. DPSC adhesion to the surface of bone cement (BC) and BC containing nanoAg (BC NpAg)
(3% w/w) after 24 h (the presented pictures are representative for 3 experiments): (A) Images from a
fluorescence microscope, Evans blue straining of cells frown on BC and BC-NpAg; (B) images from a
scanning electron microscope for BC-NpAg showing adhered cells marked by red circle.
4. Discussion
Pure bone cement is approved by the U.S. Food and Drug Administration for clinical purposes [58].
However, its modification such as additives (e.g., nanometals or antibiotics) can cause adverse effects.
Therefore, the cytocompatibility of BC containing gentamicin, nanoAg, nanoCu, or nanometals
combination was assessed in direct contact with human blood cells and dental pulp stem cells.
The presented data confirmed the cytocompatibility of the commercially available BC after a short
and a long-term exposure to both blood cells and DPSC cells (Figures 3–7, Table 3). These results are
consistent with previous reports that pure BC does not cause blood hemolysis or reduces the number
of platelets or osteocyte-like cells [10,59]. Similar results to those presented in this manuscript were
obtained for BC-A enriched with additives (i.e., gentamicin, vancomycin, or ciprofloxacin) [15–17,60].
However, we show that the exposure of DPSC cells to BCs containing gentamicin (1.5% w/w) decreased
their viability by 60% (Figure 5). It may be due to the excessive level of antibiotics as the culture
medium for DPSC is routinely supplemented with penicillin and streptomycin and on top of that,
it was enriched with specimens released from the BC. Thus, the cells might have been exposed to a
toxic dose of antibiotics [61]. It is a significant result indicating the potentially undesired effect of
combinations of antibiotics in the growth of osteoblastic progenitors.
The addition of nanoAg additives to BC (up to 3% w/w) did not affect the viability of blood cells
and DPSC cells and their antibacterial function (Figures 3–7, Table 3). These findings correspond to
previous reports demonstrating that BC with added silver is not harmful to different cell lines, including
mouse osteoblast TMOb cells (nanoAg 30–50 nm; 0.25%, 0.5%, and 1.0% w/w, after 3 days) [62], mouse
preosteoblast MC-3T3 cells (nanoAg 5 nm or 11 nm; 0.01%, 0.05%, and 1.0% w/w, after 2 days) [63,64],
human fetal osteoblast hFOB cells (nanoAg 5–50 nm; 0.1%, 0.5%, and 1.0% w/w, after 2 days) [65],
and human mesenchymal stem MSC cells (nanoAg 4000 µg/g) [66]. On the other side, the toxicity of
nanoAg was reported by other researchers. For example, BC-NpAg caused hemolysis of erythrocytes
and reduced the hBMSCs cell viability [66–68]. It should be noted that in earlier studies the routine
concentration of nanoAg was up to 1%, much lower compared to the levels studies here. Despite
that, no undesired impacts of nanoAg on the survival of blood cells and DPSC cells were observed in
our present study (Figures 3–7, Table 3). BC-NpAg up to 3% did not induce any hemolysis except it
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changed the morphology of erythrocytes after a longer 24 h exposure; it did not affect the DPSC cell
viability, their morphology, and the cells’ adhesion, and also it did not inhibit blood platelet function
(Figures 3–7, Table 3). Such discrepancy between these and previous studies may be associated with
either feature of the nanoAg itself (size or purity) or the research methodology used by the other
researchers compared with these studies. The changes in the erythrocytes’ shape in the present research
may be directly associated with long-term incubation or handling of blood (Figure 4). Determining
whether these changes are reversible and toxic requires further investigations. Surprisingly, in contrast
to nanoAg, the use of the nanoCu additives (1.5% and 3%, alone or with nanoAg) reduces blood
cells and DPSC cells viability as well as affects their morphology (Figures 3–6, Table 3). To our
knowledge, the effects of nanoCu enriched BC on its biocompatibility and cytotoxicity have not been
extensively studied. The acute toxicity of nanoCu was reported to damage the liver, the kidney, and the
spleen [69,70], and the use of nanoCu beyond the safety limits (depending on many factors) would lead
to severe cytotoxicity [71,72]. With regards to the cytocompatibility, the data on biopolymers containing
Cu are scarce. The report on nanoCu/low-density polyethylene nanocomposite intrauterine device
indicated the possibility of using nanoCu without systemic toxicity [73]. Furthermore, in the study
with no nanometric Cu, the growth of pre-osteoblast cells and their differentiation was observed [72,74].
Moreover, Cu doped bioactive glass scaffold (up to 5% w/w) demonstrated no adverse effect on the
viability of DPSC or BMSC cells and enhancing osteogenesis [34,74,75]. Different results related to
toxicity obtained in this study may be attributed to the use of Cu of nanometer size (Figures 3–6,
Table 3), potentially more dangerous than other nanoparticles. In similar studies, Cu doped bioglass
caused toxicity of human bone osteosarcoma HOS cells (2.5% w/w) [33] and human osteosarcoma
SaOS-2 cells (5% or 10% w/w) [76]. There are no reports so far on the combination of nanometals, such
as nanoAg and nanoCu, as in the present study. The obtained results demonstrated that both elements,
when added together, provoke cytotoxicity in BCs (Figures 3–6, Table 3). This means that nanoCu,
either added alone or combined with nanoAg, is harmful to cells and cannot be recommended. Some
studies on copper toxicity report that the toxic effects of Cu/nanoCu are mainly associated with ROS
production, but also they can be associated with the damage to the membrane, electron transport
disturbance, DNA damage, and results in developmental abnormalities [77].
Pure BC has no bactericidal properties, but also may contribute to infections. The use of
antibacterial additives (mainly antibiotics) allows prevention of bacteria growth on the BC [15,16].
Therefore, bactericidal properties of BC containing gentamicin (BC-A), nanoAg (BC-NpAg), nanoCu
(BC-NpCu), or nanometals (BC-NpAg+Cu) combination were assessed. This research confirmed the
bactericidal properties of all modified BCs (Figure 2, Table 2), and nanoAg was more effective than
gentamicin (Figure 2, Table 2). Those findings are consistent with previous research demonstrating that
BC or PMMA coating/film containing Ag were effective against different bacteria strains including S.
aureus (5–50 nm; 0.25%, 0.5%, and 1.0% w/w after 24 h) [44,62], S. epidermidis (5–50 nm; 0.25%, 0.5%, and
1.0% w/w after 24–48 h) [44,45,62–64], A. baumanni (5 nm; 0.25%, 0.5%, and 1.0% w/w after 24 h) [62],
MRSA (5–10 nm; 0.25%, 0.5%, and 1.0% w/w after 24 h) [62,63], P. aeruginosa (5–10nm; 0.1%, and 1.0%
w/w after 16 h) [21], E. coli (20-27 nm; after 18 h) [78]. In most of the above studies, it was found that
the appropriate concentration of nanoAg was 1% w/w, which is in line with present results (1.5% w/w
of nanoAg) (Table 2). The antibacterial effectiveness increased with the increasing content of additives.
Our observations (Figure 2) are in part supported by past research showing the reduction of biofilm
formation on the surface of the modified material [21,42,61]. The obtained results confirmed then the
superiority of nanoAg over gentamicin (Figure 2, Table 2). Some reports suggested the ineffectiveness
of BC-NpAg (5–50 nm; concentration 0.25–1% w/w) [44,79]. These discrepancies may be due to the
research methodology and a weak release of nanoAg from the BC or its non-ionized form. However, in
our current and previous studies the effectiveness of nanoAg in preventing bacteria adhesion as well
as combating surrounding bacteria was demonstrated (Figure 2, Table 2) [47]. The BCs containing
nanoCu or both nanometals have not been investigated yet. Some investigations of nanoCu in polymer
matrices and its bactericidal properties are consistent with the present results (Table 2) [80–82].
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The bactericidal effectiveness, as well as the toxic effect of nanometals, depends on its type, dose,
size, total surface area, as well as agglomeration [65,83]. In this research, two nanometals (nanoAg and
nanoCu) of equal size were used, and both showed bactericidal properties, but two different types of
cells response were observed. Hence, it can be concluded that the type of nanometals affects cytotoxicity.
Furthermore, the recent research has resulted in enlargement of Ag-based nanostructures for potential
medical and other application. This includes silver nanospheres that are created to kill effectively a
variety of bacterial and fungal strains [84]. Another example is AlOOH–Ag nanocomposite applied
against both Gram-negative and Gram-positive microorganisms in catalysis, water purification, and
biomedical applications [85]. Yet another antimicrobial nanoAg-TiO2 coating was applied for lining
leather and proved effective to prevent growth of four bacterial strains [86]. It remains unresolved why
the same dose of nanoparticles can be cytotoxic to eukaryotic cells and not to prokaryotic cells. It is
plausible this is related to the cell organization of prokaryotic and eukaryotic cells. Firstly, eukaryotic
cells are usually bigger and have higher structural and functional redundancy. Secondly, they contain
several organelles such as mitochondrion, cell nucleus, Golgi apparatus. or endoplasmic reticulum,
and these are additional diffusion barriers for nanoparticles. Thirdly, eukaryotic cells usually contain
more than one mitochondrion. Therefore, it is much more difficult for nanometals or their ions to cause
eukaryotic cell death [61,87,88]. The above explanations justify why the applied nanoAg modification
of BC is bactericidal, but it is not toxic to cells.
The present study has some limitations which indicate directions of further research. At first,
the here applied nanometals with a particle size of 50 nm were the compromise between bactericidal
effectiveness which would likely be better for smaller nanoparticles, but they would be presumably
more toxic. Secondly, this study focused exclusively on the antibacterial biological properties of BC, and
based on the obtained results, the chemical, physical, and mechanical properties of biologically best and
non-toxic BCs will be investigated soon. Thirdly, the present investigations of cytocompatibility and
bactericidal effectiveness were carried out using short-term exposure in in vitro conditions and further
research will include long-term exposure and/or in vivo tests, including additional environmental
factors, i.e., anionic ligands (such as: Chloride, inorganic sulfide) and/or proteins appearing in
biological media that may bind metallic ions or even nanometals that may be eliminated by the immune
system [65,66,89]. Finally, a thorough assessment of long-term nanometals and biological effectiveness
will be carried out.
5. Conclusions
In this study, commercially available acrylic bone cement was modified with gentamicin, nanosilver,
nanocopper, or their combination to obtain increased bactericidal properties while not deteriorating
cytocompatibility. The obtained results demonstrate that cement modified with 1.5% and 3% w/w
nanoAg or nanoCu shows a higher bactericidal effect and antibiofilm properties compared with
antibiotic-loaded bone cement. Furthermore, cement containing nanoAg (1.5% and 3% w/w) does not
influence erythrocytes hemolysis, blood platelet function, viability, morphology, and adhesion of dental
pulp stem cells. On the other hand, cement containing nanoCu (1.5% and 3% w/w) induces a shape
change and the hemolysis of erythrocytes, reduces platelet aggregation, and decreases the viability
of dental pulp stem cells. The observed differences in effects of nanoAg and nanoCu, positive and
negative, may be very specific and due to nanometric size and direct interaction of such nanoparticles
with cells or their modification of biochemical reactions. Bone cement modified with nanoAg may be
an alternative option for future clinical applications after further biological research to fully confirm
their biomechanical safety and biocompatibility, and after all the tests on their chemical, mechanical,
and physical properties are completed.
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